Sling Therapeutics, Inc., a US-based biopharmaceutical company, announced on Monday that it has named Faheem Hasnain as its new chairman of the company's board of directors.
Hasnain has served as the founder, chief executive officer, and chairman of Gossamer Bio. He also holds the position of the lead independent director for Kura Oncology and is chairman of the board of directors for Aspen Neuroscience, Mirati Therapeutics and SENTÉ. He is the former president and chief executive officer of Receptos, Facet Biotech and PDL BioPharma.
Hasnain has a BHK and a BEd from the University of Windsor.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886